Extended release composition containing tramadol

a technology of extended release and tramadol, which is applied in the direction of drug compositions, biocides, microcapsules, etc., can solve the problems of increased plasma levels, increased risk of side effects, and increased pain in patients, so as to reduce pain, effectively control pain, and effectively reduce unwanted side effects of tramadol

Inactive Publication Date: 2007-05-31
DEBOECK ARTHUR M +2
View PDF4 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0027] It is another object of the present invention to provide a once a day Tramadol pharmaceutical preparation which is able to provide effective Tramadol plasma concentration for a period of about 24 hours.
[0038] It is another object of the present invention to provide a once daily oral Tramadol preparation from which the plasma Tramadol concentration are not affected when the formulation is taken with or without food.

Problems solved by technology

This administration schedule of the drug makes it difficult for the patient to control pain, specially during night time, since pain will reappear every 4 to 6 hours.
On the other hand, if patient in an attempt to control pain for a longer period of time should take higher doses of immediate release Tramadol than peak plasma levels will increase dramatically and very serious side effects due to high blood levels will appear immediately.
Another difficulty encountered by the man skilled in the art for the production of a once daily Tramadol formulation arises from Tramadol extremely high solubility in water and body fluids.
Any once a day Tramadol formulation which should not comply with both requirements would be useless.
In vivo performance from these formulations is not available.
Tramadol is one of the examples but in vivo performances of such formulation is not available.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extended release composition containing tramadol
  • Extended release composition containing tramadol
  • Extended release composition containing tramadol

Examples

Experimental program
Comparison scheme
Effect test

example 1

Uncoated Beads

[0066]

Tramadol Hcl31.8 kgMicrocrystalline Cellulose (Avicel pH 101)21.0 KgSucrose Stearate (Crosdeta F160)2.17 kgPurified Water7.24 kg

[0067] In a planetary mixer collette of 160 liter capacity introduce the Tramadol Hcl, microcrystalline cellulose and the sucrose stearate, blend at speed 2 for about 15 min. Slowly add the purified water and continue mixing for an additional 15 minutes at speed 2 after all water is added. Extrude the blend through a Fuji Paudal extruder equipped with a 1 mm screen. Spheronize the extrudate during about 2 minutes and dry the beads in an oven at 50° C. for about 12 hours. The dried beads are screened though sieves of 1.4 and 0.7 mm. The yields of uncoated beads comprised between 0.7 and 1.4 mm was 44.0 kg (81%).

example 2

Coated Beads

[0068]

2a. Pre CoatingHydroxypropylmethylcellulose1.35 kgTalc5.40 kgPurified Water18.0 kg

[0069] 45 kg of sieved beads from Example 1 were placed in an fluidized bed coater (Aeromatic).

[0070] The beads were pre coated with 8.25 kg of the coating suspension.

2b. Sustained Release CoatingPolyacrylate (30%) Eudragit NE30D36.7 kgHydroxypropylmethylcellulose1.08 kgTalc1.08 kgPolysorbate 800.216 kg Simethicone0.540 kg Magnesium Stearate0.216 kg Purified Water18.0 kg

[0071] Immediately after the pre coatings 47.8 kg of the sustained release coating was applied onto the pre coated beads. Upon completion of the coating, the coated beads were placed onto trays in a drying oven for about 16 hours at 50° C. Upon cooling the coated beads were stored in containers for further use.

example 3

Tramadol Fast Release Tablet—30 mg

[0072]

Tramadol Hcl 3.00 kgLactose 2.63 kgAvicel pH 102 1.13 kgPovidone0.150 kgStarch0.525 kgMagnesium Stearate0.075 kg

[0073] Introduce a collette planetary mixer with a 20 liter bowl, all ingredients, except the magnesium stearate, are blend for 15 minutes at speed 2. Add the magnesium stearate and blend for about 1 minute at speed 1. The blend is compressed using dip cup punches of 5 mm diameter to produce 94,000 tablets of 75 mg containing 30 mg of Tramadol Hcl per tablet. The tablets at Example 3 were tested for release of Tramadol using USP Apparatus 1 (Paddles) in 900 mL of a buffer at pH 6.9 at 37° C. and at 50 rotations per minute.

Time [h]Tramadol Hcl Dissolved [%]0.2574.50.5098.60.75101.8

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts. The preparation provides, effective blood concentration for a period of about 24 hours with reduced peak concentrations. It is characterized that effective Tramadol levels appears within the first hours after administration, the time to maximal Tramadol content Tmax is at least 10 hours and the peak Tramadol concentration is less than three times the concentration obtained after 24 hours of said administration.

Description

CROSS-REFERENCE TO RELATED CASES [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 119,939, filed Apr. 11, 2002, which is incorporated by reference herein in its entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to a once daily extended release oral Tramadol pharmaceutical preparation which provides effective blood concentration for a period of about 24 hours with reduced peak Tramadol plasma concentrations. The formulation of the present invention provides peak Tramadol plasma concentrations that are less than twice the plasma concentration measured 24 hours after administration, while providing for effective Tramadol plasma concentration about 1 to 2 hours after administration. [0004] 2. Description of the Background [0005] Tramadol is a centrally acting synthetic analgesic compound that is not derived from natural sources nor is it chemically related to opiates. Although its mode of action is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/137A61K9/22A61K9/50
CPCA61K9/5084A61K31/137A61K31/135A61P29/00
Inventor DEBOECK, ARTHUR M.VANDERBIST, FRANCISSERENO, ANTONIO
Owner DEBOECK ARTHUR M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap